<DOC>
	<DOCNO>NCT01606722</DOCNO>
	<brief_summary>To evaluate relationship plasma intracellular darunavir ( DRV ) concentration virological efficacy HIV-infected patient DRV/rtv monotherapy .</brief_summary>
	<brief_title>Darunavir Levels , Virological Efficacy , Proviral ADN Resistances Patients Darunavir/Ritonavir Monotherapy</brief_title>
	<detailed_description>To enrol , subject plasma HIV-RNA &lt; 50 copies/mL least 6 month base , virologic failure PI-containing regimen allow genotypic resistance test show major resistance mutation associate reduced susceptibility DRV/rtv accord International AIDS Society . Patients transitory episode detectable plasma HIV-RNA viral load ( `` blip '' ) precede follow plasma viral load &lt; 50 copies/mL without change antiretroviral treatment could also include . The exclusion criterion pregnancy , hepatitis B coinfection concomitant use drug potential major interaction DRV/rtv pharmacokinetics .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Older 18 year , start antiretroviral regimen base darunavirritonavir ( 800/100 mg ) daily monotherapy June 2010 September 2010 Plasma RNAVIH &lt; 50 copies/ml stable antiretroviral treatment â‰¥ 6 month Absence resistance mutation protease gene , base treatment history and/or genotypic resistance testing . would decrease darunavir susceptibility Pregnancy Chronic B hepatitis Genotypic resistance test evidence resistance mutation protease gene would decrease darunavir susceptibility Concomitant use drug potentially adverse interaction darunavirritonavir pharmacokinetics , rifampin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Antiretroviral therapy</keyword>
	<keyword>Boosted-Darunavir monotherapy</keyword>
	<keyword>Resistance</keyword>
	<keyword>Proviral DNA-HIV</keyword>
</DOC>